RHYTHM PHARMACEUTICALS INC
For the period ended Dec 31, 2024. Filed Feb 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 28, 2025
RYTM$113.95+0.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data)
| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| · · Year Ended · · Year Ended · · Year Ended | |||||||||
| · · December 31, · · December 31, · · December 31, | |||||||||
| | 2024 | 2023 | 2022 | ||||||
| Revenues: | | | | | | | | | |
| Product revenue, net | | $130,126 | | $77,428 | | $16,884 | |||
| License revenue | | | — | | | — | | | 6,754 |
| Total revenues | | | 130,126 | | | 77,428 | | | 23,638 |
| Costs and expenses: | | | | | | | | | |
| Cost of sales | | | 13,368 | | | 9,302 | | | 2,133 |
| Research and development | | | 237,957 | | | 134,951 | | | 108,630 |
| Selling, general, and administrative | | 144,304 | | 117,532 | | 92,032 | |||
| Total costs and expenses | | 395,629 | | 261,785 | | 202,795 | |||
| Loss from operations | | (265,503) | | (184,357) | | (179,157) | |||
| Other income (expense): | | | | ||||||
| Other income (expense), net | | 2,239 | | 190 | | (790) | |||
| Gain on settlement of forward contract | | | 8,900 | | | — | | | — |
| Interest expense | | | (20,603) | | | (13,892) | | | (5,201) |
| Interest income | | 14,711 | | 13,945 | | 4,029 | |||
| Total other income (expense), net | | 5,247 | | 243 | | (1,962) | |||
| Loss before income taxes | | | (260,256) | | | (184,114) | | | (181,119) |
| Provision for income taxes | | | 346 | | | 564 | | | — |
| Net loss | | $(260,602) | | $(184,678) | | $(181,119) | |||
| Accrued dividends on convertible preferred stock | | | (3,970) | | | — | | | — |
| Net loss attributable to common stockholders | | $(264,572) | | $(184,678) | | $(181,119) | |||
| Net loss per share attributable to common stockholders, basic and diluted | | $(4.34) | | $(3.20) | | $(3.47) | |||
| | | | | | | | | | |
| Weighted-average common shares outstanding, basic and diluted | | | 60,995,204 | | | 57,673,128 | | | 52,120,701 |
| | | | | | | | | | |
| Other comprehensive loss: | | | | | | | | | |
| Net loss attributable to common stockholders | | $(264,572) | | $(184,678) | | $(181,119) | |||
| Foreign currency translation adjustment | | | 2 | | | (140) | | | — |
| Unrealized (loss) gain, net on marketable securities, net of tax | | (175) | | 366 | | (91) | |||
| Comprehensive loss | | $(264,746) | | $(184,452) | | $(181,210) | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.